Ryuji Maekawa

Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2):  <i>N</i>-Sulfonylamino Acid Derivatives

Yoshinori Tamura, Fumihiko Watanabe, Takuji Nakatani et al. · Journal of Medicinal Chemistry · 1998 · 283 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Chemical Biology +18

Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase.

Takayuki Yoshioka, Tsutomu Wada, Naoshige Uchida et al. · PubMed · 1998 · 147 citations

Chemoprevention Strategy, Immunology, Pharmacotherapy +18

Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest

Hirokazu Matsushita, Akihiro Hosoi, Satoshi Ueha et al. · Cancer Immunology Research · 2014 · 106 citations · Full text

Immune Regulation, Immunology, Immunoediting +22

Restricted V-segment usage in T-cell receptors from cytotoxic T lymphocytes specific for a major epitope of lymphocytic choriomeningitis virus

Yusuke Yanagi, Ryuji Maekawa, T Cook et al. · Journal of Virology · 1990 · 61 citations · Full text

Immunology, Viral Pathogenesis, Pathology +17

Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.

Ryuji Maekawa, Hideo Maki, Hitoshi Yoshida et al. · PubMed · 1999 · 59 citations

Tumor Biology, Angiogenesis, Matrix Metalloproteinase +15